CBD for Pets: Why 2026 Is a Turning Point for Veterinary Cannabis

The Year Vets Can Finally Talk About Cannabis

For years, veterinarians across the United States faced an uncomfortable professional paradox. Pet owners were increasingly turning to CBD products for their animals, spending hundreds of millions of dollars annually, yet most veterinarians couldn't legally discuss cannabis-derived treatments without risking their professional licenses.

That dynamic is finally shifting in 2026. A growing number of states are passing legislation that protects veterinarians from licensing board discipline when they discuss cannabis treatment options with pet owners. Maryland delegates unanimously passed such a bill in March 2026, joining California, Colorado, Oregon, and a handful of other states that have already cleared the way for open veterinary conversations about cannabinoid therapies.

The result is a sea change in how companion animal medicine approaches a substance that an estimated 30 percent of pet owners have already tried with their animals — often without any professional guidance at all.

What the Science Actually Shows

The scientific foundation for CBD use in companion animals has strengthened considerably in recent years, though it remains far from comprehensive. The most compelling evidence exists for canine osteoarthritis, where multiple controlled studies have demonstrated meaningful improvements in pain, mobility, and quality of life metrics.

A landmark Cornell University study found that CBD oil administered at 2 mg/kg twice daily significantly decreased pain and increased activity in dogs with osteoarthritis, with no observable side effects reported by owners. Subsequent studies have replicated these findings, establishing canine joint pain as the best-supported veterinary application for CBD.

Beyond arthritis, research has shown promise in several other areas. Dogs with epilepsy have demonstrated reduced seizure frequency when CBD was added to conventional anticonvulsant medications, though CBD alone was not sufficient to control seizures in most cases. Studies examining CBD for canine anxiety, including separation anxiety and noise phobias, have shown mixed but generally encouraging results.

For cats, the available data remain more modest, but safety studies confirm good tolerance at correctly set doses. Feline research is proceeding more slowly in part because cats metabolize cannabinoids differently than dogs, with longer half-lives and potentially different therapeutic windows.

The Critical Safety Distinction: CBD vs. THC

One point that veterinary professionals emphasize above all others is the critical distinction between CBD and THC when it comes to animal safety. While CBD appears to have a favorable safety profile in dogs and cats at appropriate doses, THC is toxic to companion animals even in small amounts.

Dogs have a higher density of cannabinoid receptors in their brains compared to humans, making them significantly more sensitive to THC's psychoactive effects. Signs of THC toxicity in dogs include ataxia (loss of coordination), urinary incontinence, dilated pupils, excessive drooling, and in severe cases, seizures or coma.

The American Veterinary Medical Association reports that cannabis toxicity cases in pets have increased dramatically as legal markets have expanded, primarily from animals accidentally ingesting THC-containing edibles. This trend underscores the importance of keeping all cannabis products — especially edibles that may smell appealing to animals — securely stored and out of reach.

A $600 Million Market With Growing Pains

The pet CBD market is expected to reach approximately $600 million in 2026, with a compound annual growth rate of 33 percent projected through the next decade. That rapid growth has attracted both legitimate manufacturers committed to quality and safety, and opportunistic brands looking to capitalize on consumer enthusiasm without investing in proper formulation or testing.

The category has expanded well beyond basic hemp oil drops. Today's market includes breed-specific formulations calibrated to typical body weights, condition-targeted products designed for joint support, calming, or digestive health, and increasingly sophisticated delivery formats including soft chews, topical balms, and even transdermal patches designed for pet application.

Quality control remains the industry's most significant challenge. Third-party laboratory verification has become the minimum standard for reputable brands, with certificates of analysis confirming cannabinoid content, the absence of THC above trace levels, and screening for pesticides, heavy metals, and microbial contamination.

Dosing: What Veterinarians Recommend

Now that more veterinarians can openly discuss CBD with clients, a clearer picture of dosing guidelines is emerging. Most veterinary recommendations start with a low dose — typically 1 to 2 mg of CBD per kilogram of body weight, administered twice daily — and adjust based on the animal's response over two to four weeks.

Veterinary professionals caution against the "more is better" approach that some pet owners adopt. While CBD has a relatively wide safety margin in dogs, very high doses have been associated with elevated liver enzymes in some studies, suggesting that liver function should be monitored in animals receiving CBD long-term, particularly those already taking medications metabolized by the liver.

The form of CBD matters as well. Oil-based tinctures administered directly into the mouth or mixed with food tend to have the most predictable absorption. Treats and chews may have variable cannabinoid distribution, meaning one treat in a bag might contain significantly more or less CBD than another from the same batch.

The FDA Question

Despite the growing body of evidence and expanding state-level protections for veterinary discussions, CBD products for animals remain in a regulatory gray zone at the federal level. The FDA has not approved any CBD product for use in animals, and the agency has issued warning letters to companies making unsubstantiated therapeutic claims about their pet CBD products.

This regulatory uncertainty means that veterinarians who discuss CBD with clients are sharing information about an unapproved substance, even in states where they're legally protected from professional consequences for doing so. Most veterinarians frame their guidance carefully, presenting the available evidence while noting the limitations and encouraging owners to use only products with verified third-party testing.

Looking Forward

The trajectory of veterinary cannabis is moving in one clear direction: toward greater acceptance, more rigorous research, and better-regulated products. As additional states pass legislation protecting veterinary discussions of cannabinoids, the profession's collective knowledge base will expand rapidly.

Clinical trials specifically designed for veterinary applications are underway at several major research universities, with results expected to strengthen the evidence base over the next two to three years. These studies are examining not just CBD in isolation, but specific cannabinoid ratios and formulations optimized for common veterinary conditions.

For pet owners considering CBD for their animals, the advice from veterinary professionals is consistent: start with a conversation with your vet, choose products from reputable manufacturers with transparent third-party testing, begin with low doses and adjust gradually, and never use products containing THC. The era of guessing in the dark is ending — and both pets and their owners stand to benefit.